The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus

Hormone and Metabolic Research

Volumn 34, Issue 9, 2002, Pages 504-508

  Fineman, M ^a   Weyer, C ^a   Maggs, D G ^a   Strobel, S ^a   Kolterman, O G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Beta Cell Hormones; Glucagon; Hyperglycemia; Insulin; Islet Hormones

Indexed keywords

AMYLIN DERIVATIVE; GLUCAGON; INSULIN; PLACEBO; PRAMLINTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERGLUCAGONEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RISK; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TEST MEAL; TREATMENT OUTCOME;

ADULT; AMYLOID; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 0036751254     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34790     Document Type: Article

References (31)

1. Moore CX, Cooper GJS. Co-secretion of amylin and insulin from cultured islet beta cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun 1991; 179: 1-9
2. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenberg E, Brunnbauer M, Woloszczuk W, Prager R. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991; 34: 52-54
3. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Des 2001; 7: 1353-1373
4. Brom AK, Klevesath MS, Borcea V, Kasperk C, Seibel MJ, Wahl P, Ziegler R, Naworth PP. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm Metab Res 1999; 31: 472-475
5. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: Potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol Ther 2002; 4: 175-189
6. Young A, Moore C, Herich J, Beaumont K. Chapter 9: Neuroendocrine actions of amylin. In: Poyner D, Marshall I, Brain S (eds). Calcitonin Gene-Related Peptide (CGRP). Austin, Texas: R.G. Landes, 1999: 91-102
7. Koda JE, Nyholm B, Fineman MS, Hove KY, Schmitz O. Plasma concentrations of amylin reflect insulin sensitivity in relatives of patients with NIDDM and in healthy subjects. Diabetologia 1996; 39: A68 (abstract 250)
8. Fineman MS, Giotta MP, Thompson RG, Kolterman OG, Koda JE. Amylin response following Sustacal® ingestion is diminished in type II diabetic patients treated with insulin. Diabetologia 1996; 39: A149 (abstract 566)
9. Scherbaum WA. The role of amylin in the physiology of glycemic control. Exp Clin Endocrinol Diabetes 1998; 106: 97-102
10. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. Pramlintide: A human amylin analog reduced postprandial plasma glucose, insulin and c-peptide concentrations in patients with type II diabetes. Diabet Med 1997; 14: 547-555
11. Ratner R, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther 2002; 4: 51-61
12. Fineman M, Gottlieb A, Skare S, Kolterman O. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 2 diabetes during treatment for 52 weeks. Diabetes 2000; 49: 106 (428-P)
13. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. Diabetes Care 1998; 21: 987-993
14. Kong MF, Stubbs T, King P, Lambourne J, Macdonald I, Blackshaw E, Perkis A, Parker J, Tattersall R. Effect of single doses of pramlintide on gastric emptying of two meals in type 1 diabetes. Diabetologia 1998; 41: 577-583
15. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol 2000; 278: G946-G951
16. Young AA, Gedulin B, Vine W, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995; 38: 642-648
17. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24: 371-381
18. Silvestre RA, Rodriguez-Gallardo J, Jodka C, Parkes DG, Pittner RA, Young AA, Marco J. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol 2001; 280: E443-E449
19. Unger RH, Orci L. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu Rev Med 1977; 28: 119-130
20. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 106-110
21. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995; 109: 755-765
22. Wahren J, Felig P, Hagenfeldt L. Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Invest 1976; 57: 987-999
23. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053-4059
24. Percy AJ, Trainor DA, Rittenhouse J, Phelps J, Koda JE. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 1996; 42: 576-585
25. Fineman MS, Koda JE, Shen LX, Strobel SA, Maggs DG, Weyer C, Kolterman OG. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002; 51: 636-641
26. Gedulin B, Percy A, Jodka C, Young A. Endogenous amylin inhibits glucagon secretion, as demonstrated by studies using neutralizing antibody and the antagonist AC187. Diabet Med 1997; 14: S18 (abstract 5)
27. Gedulin BR, Rink TJ, Young AA. Dose response for glucagonostatic effect of amylin in rats. Metabolism 1997; 46: 67-70
28. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 1994; 62: 553-567
29. Edwards GL, Gedulin B, Jodka C, Dilts R, Miller C, Young A. Area postrema (AP)-lesions block the regulation of gastric emptying by amylin. Neurogastroenterol Motil 1998; 10: 26
30. Lutz TA, Delprete E, Scharfer E. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides 1995; 16: 457-462
31. Taborsky GJ, Ahren B, Havel PJ. Autonomic mediation of glucagon secretion during hypoglycemia: Implications for impaired α-cell responses in type 1 diabetes. Diabetes 1998; 47: 995-1005